Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.

Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products.

Read Article: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/cingulate-inc-announces-pricing-25-020500801.html

 

Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.2022-01-06T15:45:44+00:00

Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering

Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.”
Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering2022-01-10T05:30:29+00:00

Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.

Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities
Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.2022-01-10T05:34:18+00:00

Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).

The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for BioSig over the course of our decade long relationship and look forward to watch the company continue to execute.

Read Article: https://ir.biosig.com/press-releases/detail/278/biosig-announces-closing-of-public-offering-of-common-stock

Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).2021-07-12T10:13:09+00:00

How advisor platforms are changing the offshore industry

Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for advisors who opt for this independent model?

The entrepreneurial spirit is strong in the advisory industry, with a growing number of international advisors now making the jump to independence. But launching an RIA can prove a time-consuming and costly venture that also requires negotiating crucial third-party agreements with a range of service providers.

Read Full Article Here

How advisor platforms are changing the offshore industry2021-07-07T03:33:04+00:00

Laidlaw expands international business with new Miami-area office

Laidlaw Wealth Management has hired an advisor from Wells Fargo’s international unit in Miami as the firm looks to expand its coverage of Latin America with the opening of a new office. John Cross joined the firm on May 5 after having spent nearly seven years at the wirehouse’s offices in Coral Gables, according to his BrokerCheck profile. He oversees around $100m in assets for clients based mostly in Argentina as well as in the US.

Read Full Article Here

Laidlaw expands international business with new Miami-area office2021-07-07T03:28:47+00:00

Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $125,000,000 Follow-On Offering for Aldeyra Therapeutics.

Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel Aldeyra’s excellent execution in developing its pipeline and delivering results for patients and investors.

Read Article: Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $125,000,000 Follow-On Offering for Aldeyra Therapeutics.2021-04-30T19:48:54+00:00
Go to Top